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Abstract
Background: The COVID-19 pandemic has caused major disruption to healthcare services globally and has
impacted on tuberculosis (TB) patients and TB diagnosis and treatment services both in low- and high-income
countries. We therefore explored the perspectives of members of regional and international TB control and research
networks to further understand TB service disruptions and compared the experiences of members from West
African and European countries.
Methods: This cross-sectional, explorative descriptive study was conducted from May to July 2020 using an open
online survey with target respondents from both West African and European countries. The survey comprised
discrete questions exploring challenges faced with TB screening, diagnosis, treatment, prevention, and changes
implemented. Additionally, respondents were asked to provide recommendations for remedial actions.
Results: We analysed responses from 124 respondents based in 29 countries located in Europe and West Africa.
About half of the respondents reported challenges in delivering routine TB services during the COVID-19 pandemic,
with over one third reporting having some form of guidance issued regarding maintaining delivery of routine TB
services. Respondents emphasised the need for strengthening TB services especially in light of COVID-19 pandemic.
Considerable similarities were found between the challenges experienced by TB professionals in both West African
and European settings. Responses also highlighted the hidden challenges faced in some countries prior to the
COVID-19 pandemic, especially in some West African settings where staff shortages and laboratory issues predated
COVID-19.
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Conclusions: TB control and research professionals in West African and European settings experienced similar
challenges to the delivery of TB diagnosis and treatment services due to the COVID-19 pandemic, and highlighted
the need for clear communication of guidelines, prioritisation of routine TB service delivery, ongoing health
education, and possible integration of TB and COVID-19 services to ensure that TB services are more resilient
against the impact of the pandemic.
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Background
The Coronavirus Disease-2019 (COVID-19) was de-
clared a pandemic by the World Health Organization
(WHO) on 11 March 2020 [1]. Since then, COVID-19
has caused extensive disruption to routine services for
the control of both communicable and non-
communicable diseases worldwide. This disruption,
which could have far-reaching consequences, has contin-
ued well into 2021 and will most likely extend beyond
[2, 3]. Low-income and high-income countries have been
impacted by the pandemic, but the extent and pattern of
the impact on routine health service delivery is still
unfolding. Many low- and middle-income countries
(LMIC) who were already battling high burdens of infec-
tious diseases such as tuberculosis (TB) are likely to feel
the impact of this disruption to a greater extent due to
disruption of their health services [4, 5]. Similarly, many
high-income countries (HIC) have experienced severely
disrupted laboratory services due to the COVID-19 pan-
demic [6].
In recent years, some progress has been made in redu-
cing the burden of TB, and ambitious targets have been
set for reaching the WHO End TB Strategy targets of
90 % reduction in new TB cases and 95 % reduction in
TB deaths by 2035, compared to 2015 [7]. However,
many national TB control programmes are already fa-
cing major interruptions to their routine services, which
could result in major setbacks, compounding the direct
impact of COVID-19 [2, 4]. The impact of those disrup-
tions has been estimated to have potentially resulted in
up to 400,000 excess TB deaths in 2020, reverting the
global situation to levels seen one decade ago [8]. Mod-
elling studies also indicate that the COVID-19 pandemic
could result in up to 6.3 million additional TB cases glo-
bally between 2020 and 2025 [3]. These consequences
are envisaged to be global, with both LMIC and HIC
having their share of the outcomes [6, 9].
Some of the causes for these outcomes include the
additional pressure on health service resources due to
the COVID-19 pandemic, reductions in the number of
health facilities offering TB diagnostic and treatment
services, reallocation of TB staff to the COVID-19 re-
sponse, and concerns about stigma given the similarities
in clinical presentation of TB and COVID-19 [3]. Taken
together, the impact of COVID-19 on TB control
services could slow or reverse progress towards WHO
End TB Strategy targets, especially in high TB burden
countries [10].
The WHO has issued several recommendations to
member states to help mitigate the effects of the pan-
demic. These included maximising remote care and sup-
port for TB patients by using digital technologies,
reducing the number of visits to health services during
treatment, ensuring adequate infection prevention and
control, and maintaining TB preventive treatment [3,
11].
With this survey, we sought to capture the experiences
of healthcare professionals who work in TB-related ser-
vices in West African and European countries, with a
view to describe and compare the impact of the COVID-
19 pandemic on routine TB services in both settings.
We also sought to determine which measures and pol-
icies have been put into place to mitigate the effects of
the pandemic on TB services, and to seek recommenda-
tions for reducing disruptions.
Methods
Study design, population and sampling method
We conducted a cross-sectional, exploratory descriptive
online survey from May to July 2020 using a Google
form designed to capture quantitative and qualitative
data from respondents. The survey was carried out in
accordance with research ethics and governance guide-
line of the UK National Health Services (NHS) Health
Research Authority. Our target population were mem-
bers of several international TB control and research
networks. These included: (i) the West African Regional
Network for TB Control (WARN-TB), which is a large
network of national TB programme (NTP) managers
from national Ministries of Health in West African
countries; (ii) the TB network within the West African
Networks of Excellence for TB, AIDS and Malaria
(WANETAM) – a research capacity building network in
West Africa that is funded by the European and Devel-
oping Countries Clinical Trials Partnership (EDCTP);
(iii) the West African Paediatric TB Network (WApTB-
Net) – a subnetwork within WANETAM; and (iv) the
Paediatric Tuberculosis Network European Trials Group
(ptbnet) - a research network of > 300 clinicians and re-
searchers based at 128 healthcare institutions across 31
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European countries [12]. Members of these collaborative
networks include policy makers, general physicians, pae-
diatricians and paediatric subspecialists, nurses, clinical
and laboratory research scientists with interest in adult
and paediatric TB. We used a purposive sampling
method with the aim to enrol as many participants as
possible from each of the networks.
Survey
We created an on-line survey that was aimed at address-
ing the impact of a novel global health challenge, and
thus did not use any previously validated questionnaire.
The online survey was designed in English by the study
team comprising members with expertise in clinical and
social science research related to TB treatment and con-
trol both in West Africa and Europe. The survey ques-
tions were initially piloted with five healthcare workers
involved in TB control and research programme from
The Gambia, Benin Republic, Nigeria and the United
Kingdom, allowing us to refine the questions and op-
tions for responses. We then shared the final survey
Google form to potential respondents through the
broadcast email group addresses and WhatsApp chat
groups of the respective networks.
The 11 survey questions aimed at understanding the
experience and perspectives of the respondents regard-
ing TB services in their respective localities and coun-
tries during the COVID-19 pandemic. The first ten
questions captured the respondent’s country of work,
profession, number of COVID-19 cases nationally at the
time of completing the survey, followed by single-choice
questions (“Yes”, “No” or “Don’t know”) with space to
add open response text if “Yes” was selected. The last
question was an open response question on what mea-
sures the respondent would like to be put in place for
TB control during the COVID-19 pandemic in their re-
spective country. The survey was administered in Eng-
lish. The Google survey form with the fields used for the
subsequent extraction of quantitative and qualitative
data is included in the Supplementary information (see
Additional file 1).
Ethical approval, data management and analysis
Research ethics committee review is not required for re-
search involving healthcare staff recruited as research
participants by virtue of their professional role (Govern-
ance Arrangements for Research Ethics Committees,
paragraph 2.3.14) [13]. We therefore did not apply for a
formal ethical approval. The survey had an introductory
text stating its purpose and that the survey was com-
pletely anonymous, and informed consent was implied
by respondents agreeing to participate in and completing
the survey.
The quantitative and qualitative data obtained from
the survey were downloaded into an Excel document.
We analysed the quantitative data using Stata 16 (Stata-
Corp, Texas, USA) for descriptive summary statistics
(frequencies and percentages).
For the qualitative data, responses to the open-ended
questions were analysed thematically using a deductive
framework approach [14]. This involved reading and re-
reading the dataset to develop familiarity with the data.
We then iteratively developed a coding and thematic
framework that identified important elements related to
the survey questions. Initial themes were determined
based on the prevalence of recurring responses across
the dataset as well as the relevance of themes for an-
swering the survey question. From this process, the over-
arching themes and corresponding sub-themes for each
question were identified.
Results
A total of 124 survey responses were received from re-
spondents who reported about 29 countries. Given the
networks approached, the survey respondents reported
their experiences on the countries in in West Africa and
in Europe as expected. A map showing the geographical
distribution of survey respondents is included in the
Supplementary information (see Additional file 2).
The majority of the respondents were from West Af-
rica (n = 72; 58 %), and identified themselves as health-
care professionals, comprising doctors or nurses (n = 88;
71 %). The distribution of the survey respondents by oc-
cupation and country classification is shown in Table 1.
Challenges within routine TB services
While half of the respondents reported that there were
general challenges with routine TB screening and diag-
nosis during the COVID-19 pandemic, 56.5% of the re-
spondents did not think it was more difficult to access
routine TB treatment and prevention services . The dis-
tributions were similar in both West African and Euro-
pean settings (Table 2). However, a higher proportion of
respondents from West Africa, relative to Europe, re-
ported increased difficulty for presumptive TB cases to
access TB diagnosis and care services (36.1% vs. 21.1%),
and for patients on TB treatment to receive their TB
drug supply including by direct observation of treatment
(DOT) (25% vs.17.3%).
The narratives, however, that emerged from the
open-ended questions suggested that there have been
interruptions of routine TB services in both West
African and European settings, as summarised in
Figure 1, and the Supplementary information (see
Additional file 2).
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Challenges with accessibility
Reduction in clinic attendance was reported from both
settings, with respondents citing reasons such as ‘fear of
COVID-19’or restriction of movement as being respon-
sible for this. In some instances where people with pre-
sumed TB sought care, they were unable to access care
due to policies restricting visits to health facilities, or in
other instances, complete closure of the health facility
due to the pandemic. Concerning this issue, one re-
spondent stated that: “[this] has resulted in three deaths
that I am aware of” (Healthcare Professional, UK).
Furthermore, many respondents reported challenges
with Healthcare Workers (HCWs) staffing in their set-
tings. There were staff shortages in TB services because
HCWs were unable to get to work due to the lockdown
or due to being drafted into COVID-19-related work.
Some HCWs were reluctant to work for fear of contract-
ing COVID-19 due to lack of appropriate personal pro-
tective equipment (PPE).
Unique to the West African setting was the challenge
of stigma, with HCWs said to be presumptively labelling
any cough as possible COVID-19 and/or ‘run away from
anybody coughing’ in some instances.
Challenges with screening and diagnosis
Respondents from West Africa expressed challenges
with laboratory services, mentioning issues such as lack
of laboratory diagnostic materials, such as GeneXpert
cartridges, and diversion of scarce TB laboratory equip-
ment, such as GeneXpert machines, to COVID-19 ser-
vices. While some participants reported shortages,
others experienced laboratory equipment breakdowns.
This typically resulted in a general slowing down of
diagnostic services. As stated by one respondent, the re-
ported challenges in some West African countries
reflected problems that often existed prior to the emer-
gence of COVID-19:
Table 1 Overview of the main occupation of survey respondents
Occupation Overall (n = 124) West Africa (n = 72) Europe (n = 52)
Healthcare professional, n (%) 88 (71.0) 41 (56.9) 47 (90.4)
Academic researcher, n (%) 13 (10.5) 9 (12.5) 4 (7.7)
Public health official, n (%) 13 (10.5) 13 (18.1) 0
TB programme manager, n (%) 6 (4.8) 5 (6.9) 1 (1.9)
Lab-based scientist, n (%) 4 (3.2) 4 (5.6) 0
Table 2 Challenges in assessing routine TB screening, diagnosis, treatment and prevention services in countries during the COVID-
19 pandemic
Variables Overall (n = 124) West Africa (n = 72) Europe (n = 52)
Are there general challenges with routine TB screening and diagnosis?
Yes, n (%) 62 (50.0) 37 (51.4) 25 (48.1)
No, n (%) 54 (43.5) 30 (41.7) 24 (46.1)
Don’t know, n (%) 8 (6.5) 5 (6.9) 3 (5.8)
Are there general challenges with routine TB treatment and prevention?
Yes, n (%) 46 (37.1) 28 (38.9) 18 (34.6)
No, n (%) 70 (56.5) 39 (54.2) 31 (59.6)
Don’t know, n (%) 8 (6.4) 5 (6.9) 3 (5.8)
Is it more difficult for presumed TB patients to access diagnosis and care services?
Yes, n (%) 37 (29.8) 26 (36.1) 11 (21.1)
No, n (%) 75 (60.5) 41 (56.9) 34 (65.4)
Don’t know, n (%) 12 (9.7) 5 (6.9) 7 (13.5)
Is it more difficult for TB patients to receive their TB drug supply or to have direct observation of their treatment?
Yes, n (%) 27 (21.8) 18 (25.0) 9 (17.3)
No, n (%) 87 (70.2) 49 (68.1) 38 (73.1)
Don’t know, n (%) 10 (8.0) 5 (6.9) 5 (9.6)
Abbreviations: TB tuberculosis
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“[This] has been an issue even before the pan-
demic… However, the pandemic has worsened the
situation…” (Public Health Official, Nigeria)
Conversely, the main challenges noted by European re-
spondents were reductions in the frequency and quality
of routine services, with TB screening services com-
pletely halted in some settings. Many respondents re-
ported that they had to resort to the use of the
interferon-gamma release assay (IGRA) for TB screening
to avoid repeated face-to-face contact required for tuber-
culin skin testing.
Challenges with treatment and prevention
Survey respondents from both West African and Euro-
pean countries reported a disruption in TB treatment
monitoring by DOT, as well as shortages in both first
line and second line TB medication. These shortages
coupled with repurposing of some/several drug
resistant-TB (DR-TB) treatment centres into facilities
providing COVID-19 care resulted in DR-TB patients
having serious challenges in accessing treatment in some
locations.
“There is a shortage of few drugs (INH+Pyridoxine
100 mg combi tablet, rifampicin oral solution, etc).”
(Academic Researcher, Germany).
“Shortages with some anti-TB drugs was experi-
enced due to delay in delivery from central and
zonal stores.” (Public Health Official, Nigeria).
In some European countries however, HCWs resorted
to Video-Observed Therapy (VOT) and follow-up via
telephone calls. In both settings, respondents stated that
Fig. 1 Key themes and subthemes that emerged from the open-ended questions
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TB patients had to be given their medications for longer
durations at a time, with limited follow-up visits to as-
sess compliance.
Additionally, reports of disruption in BCG vaccination
services were common in both West Africa and Europe,
with up to 25% of eligible infants reported to have
missed their neonatal doses of the vaccine in some set-
tings. Some participants commented that contact tracing
and migrant screening had slowed or even been
suspended.
Measures and policies to maintain routine TB services
Fewer than a third (33/124; 26.6%) of the respondents
from both settings reported that specific guidance had
been issued, at the national or regional level in their re-
spective countries, regarding maintaining continuation
of routine TB screening, diagnosis, prevention and treat-
ment services during the pandemic. However, 29% of re-
spondents in West Africa were unaware of any national
or regional guidelines or policies, compared to less than
10% in Europe (Table 3).
Some of the measures and policies put in place to en-
sure continuation of services included Standard Operat-
ing Procedures (SOP) and guidelines at national and
regional levels. The respondents also highlighted that
there were policies to guide the integration of services
for TB and COVID-19, with awareness campaigns on in-
fection prevention and control, appropriate use of PPE,
and safety in the work environment targeted at health
care workers. In both settings, respondents commented
that patients were given their TB medication supplies
for longer periods than usual to reduce the number of
visits to health facilities. In most instances, these policies
were disseminated by mail, email or social media, and in
a few instances the respondents provided links to rele-
vant websites [15, 16].
Recommendations made by study respondents
There were fewer responses from Europe (37%) com-
pared to West Africa (56%) on the question of recom-
mendations for workable solutions and lessons learnt
during the pandemic. Qualitative responses from West
African countries underscored the need for clear commu-
nication of recommendations and guidelines at national
and regional levels to guide the TB delivery services, espe-
cially during potentially disruptive situations such as the
COVID-19 pandemic. Conversely, no respondent from
Europe mentioned this recommendation.
“I would like that there was a statement/guidance
from the NLTP to guide the operation/sustenance of
TB services during this period.” (Healthcare Profes-
sional, The Gambia)
“I think there should be a clear guidance for routine
screening, diagnosis and treatment for tuberculosis
in this COVID-19 pandemic to all facilities.” (La-
boratory-based Researcher, Ghana)
Another recommendation highlighted by respondents
from both settings was the need for strengthening TB
services by ensuring availability of diagnostic tools and
medication, as well as supporting staff wellbeing, not-
withstanding the pandemic. Many specifically mentioned
the necessity for this to continue despite the COVID-19
pandemic. Also highlighted was that TB programmes
needed to ensure that staff within TB services are viewed
as “essential”, ‘so as to protect them from redeployment
to emergency services as part of the COVID-19 response’
(Healthcare Professional, UK).
“The urgency of uncompromised TB diagnostics/treat-
ment and follow up should be a national concern…
Diagnostics and interprofessional exchange should not
be compromised for TB patients during the COVID
pandemic.” (Healthcare Professional, Austria)
“[There should be] encouragement of TB programme
officers and other health care professionals by pro-
viding enough PPE and other incentives for them to
Table 3 Country/region specific guidelines to maintain routine TB services
Variables Overall (n = 124) West Africa (n = 72) Europe (n = 52)
Is there a country-specific guidance for routine screening, diagnosis, prevention or treatment of TB during the COVID-19 pandemic published?
Yes, n (%) 33 (26.6) 21 (29.2) 12 (23.1)
No, n (%) 67 (54.0) 30 (41.6) 37 (71.1)
Don’t know, n (%) 24 (19.4) 21 (29.2) 3 (5.8)
Is there a region-specific guidance for routine screening, diagnosis, prevention or treatment of TB during the COVID-19 pandemic published?
Yes, n (%) 26 (21.0) 17 (23.6) 9 (17.3)
No, n (%) 72 (58.0) 34 (47.2) 38 (73.1)
Don’t know, n (%) 26 (21.0) 21 (29.2) 5 (9.6)
Abbreviation: TB tuberculosis
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be able to do more.” (Healthcare Professional,
Nigeria)
As many as 25% of respondents from West African
countries recommended that TB programmes should
take advantage of the current situation for active case
finding by testing or screening all COVID-19 suspects
for TB. Some of the suggestions offered included ‘apply-
ing the cough questionnaire to screen for TB’ and ‘concur-
rent TB screening among suspected COVID-19 patients
who present with cough’.
There was also emphasis on the need for intensified
health education to remind the world ‘not to forget TB’
and to make people aware that ‘chronic cough may not
just be COVID’. As stated by one respondent:
“There needs to be more public education on TB
since COVID-19 has overshadowed the education on
other health conditions” (Healthcare Professional,
Ghana).
It was also proposed by several respondents in both
settings that there is need to consider alternatives to the
current face-to-face consultations and DOT practices in
the post-COVID era. Their suggestions included virtual
medical consultations, remote monitoring of treatment,
and home visits for delivery of medication, even beyond
the pandemic. As stated by one respondent, we should
‘remember the value of remote monitoring for post-
COVID to avoid unnecessarily long in-patient stay for
observation.’ (Healthcare Professional, UK)
Discussion
Our survey of 124 members of international TB control
and research networks provides evidence of the impact
of COVID-19 on routine TB services in low-income as
well as in high-income settings from those at the front
line of TB services. We found considerable similarities
in the challenges to delivery of routine TB services expe-
rienced by service providers in both settings. Three main
challenges were identified, namely, challenges with ac-
cessibility, challenges with screening and diagnosis, and
challenges with treatment and prevention. The survey
highlights some specific measures and policy adaptations
that were implemented to reduce disruptions. We also
detail the recommendations offered by members of the
networks, many of whom are frontline healthcare
workers in TB diagnosis and treatment services, to miti-
gate the impact of the pandemic on TB services. These
include the need for clear communication on mainten-
ance of routine services during similar situations, the
need to re-prioritise routine TB services to ensure that
they continue without interruption despite the COVID-
19 pandemic, and the need for continued health
education of the public, and the need for innovative al-
ternatives to the current TB care practices.
Our findings are similar to that of a recent report on a
survey by Khan et al., which also found that access to
TB services for both healthcare providers and patients
had been substantially affected during the pandemic [2].
Although that survey was exclusively conducted in
LMICs, findings from a broader range of HCWs in our
study suggest that both low- and high-income settings
had very similar experiences of reduced access to TB
services, with consequent TB-related deaths reported in
some instances. These findings suggest that it is impera-
tive to re-focus resources to TB services to mitigate the
impact of COVID-19 on TB, where these services are
based [8].
Our survey findings also suggest that due to the pan-
demic, routine TB preventive services such as screening
for latent TB infection and administration of BCG vac-
cine were adversely affected. These changes were as
forecast by researchers who anticipated that TB services
would become more focused on the care of active TB
disease rather than prevention [9]. Deployment to
COVID-19 services, HCWs being off duty due to sick-
ness or self-isolation, and the concern that social contact
within clinical spaces may result in more COVID-19
transmission are reasons for these observations [9]. We
found this to be the case in our survey, in both West Af-
rica and Europe.
The pandemic has also exposed some of the pre-
COVID-19 frailties in the health systems. For example,
the pre-existing regular anti-TB therapy stock-outs in
West Africa and some European countries became exac-
erbated and more apparent due to the disruption of sup-
ply chains worldwide [17, 18]. Similarly, in many West
African countries where there have been pre-existing
weak healthcare systems, the diversion of political will
and scarce human resources to the COVID-19 response
have further hampered routine TB services [3].
Fewer than a third of the respondents reported that
they were aware of guidance or policy adaptations to
maintain TB services during the pandemic. This finding
suggests a need for facilitated information sharing from
central, national or regional offices to frontline HCWs,
as recommended by our respondents [2]. Adaptations,
particularly in West Africa, could include incorporating
TB and COVID-19 services, and concerted dissemin-
ation of COVID-19 and TB health education and
stigma-reduction messages [19]. Integrating knowledge
and awareness of TB into the health education for front-
line HCWs and community education on behavioural
practices such as cough etiquette and infection preven-
tion and control may ultimately contribute to the reduc-
tion of TB transmission [20]. These, in addition to the
need to ensure that TB services remain resilient
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throughout pandemic situations are crucial if the End
TB targets of 2030 are to be met [21, 22].
As recommended by the respondents, there is a need
for innovative alternatives to the traditional DOTs and
frequent clinic visits for TB care which were being prac-
ticed in the pre-COVID-19 era. Notably, the COVID-19
situation presents an opportunity for a re-evaluation of
the current policies and practices of delivery of TB care.
The need to reduce clinic attendance during the pan-
demic may equally present the opportunity to strengthen
home-and-community-based care and exploring virtual
means of medical consultation and care [23].
Our survey highlights the nature of the impact of
COVID-19 on TB service delivery with European and
West African countries similarly affected. As experiences
are shared between countries and across income set-
tings, solutions and policies applied in one setting could
be adapted for use in another [24, 25]. Additionally, the
COVID-19 pandemic remains fluid, and ongoing
changes imply that the recommendations might require
many adaptations.
Our survey has some notable limitations: the overall
small sample size may not be fully representative of the
populations surveyed. The total number of respondents
who filled out the survey, and even smaller number who
responded to the qualitative aspects might limit the gen-
eralisability of our findings. Considering that the survey
was conducted during the peak of the first wave of the
pandemic, we acknowledge that if repeated now, the
findings might be different. Furthermore, in the context
of the ongoing COVID-19 pandemic, to encourage par-
ticipation and to avoid diverting substantial time away
from clinical duties, we decided to focus on only a rela-
tively small number of key variables. Also, we provided
examples of answers to some of the qualitative aspects
of the survey as guides for our respondents. Taken to-
gether, these may have limited the spread and diversity
of responses obtained in the open-ended questions. We
also recognise that the availability of the survey in Eng-
lish language only may have led to the self-selection of
participants, and we may have missed professionals who
do not speak English.
Conclusions
Our survey of frontline professionals highlights the simi-
larities in challenges in accessing and maintaining rou-
tine TB services during the COVID-19 pandemic in
West African and European settings. Their recommen-
dations to mitigate the impact include prioritisation of
routine TB service delivery to ensure that they are more
resilient against future epidemics, ongoing health educa-
tion, and integration of healthcare delivery services.
They also stressed the need for clear communication of
guidelines in the future and suggested the need for
innovative ways of delivering TB care. These concerted
efforts are needed to ensure that the targets of the
WHO’s End TB Strategy can be achieved.
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